DFO
ISEE

Duquesne Family Office’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Duquesne Family Office’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-400,000
Closed -$9.73M – 68
2023
Q1 		$9.73M Buy
+400,000
New +$8.76M 0.42% 30

Other funds holding ISEE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Duquesne Family Office's ISEE Position: Q2 2023 in Review

Duquesne Family Office sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2023, closing a stake of 400,000 shares — an estimated $9.73M sold.

Duquesne Family Office first reported a position in ISEE in Q1 2023 and held it in 1 quarter. The position peaked at $9.73M in Q1 2023. 256 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.

  • Duquesne Family Office reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Duquesne Family Office sold 400,000 IVERIC bio, Inc. Common Stock shares in Q2 2023, an estimated $9.73M.
  • Duquesne Family Office first reported a position in IVERIC bio, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Duquesne Family Office's IVERIC bio, Inc. Common Stock position peaked at $9.73M in Q1 2023.
  • 256 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2023.

Based on Duquesne Family Office's 13F filing for Q2 2023, filed 14 Aug 2023.